Dazucorilant 300 mg

Phase 2

Corcept Therapeutics Incorporated (CORT)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Oct '26

CORTPhase 2$8.6B

Dazucorilant 300 mg Phase 2 Est. Readout

Dazucorilant 300 mg• Amyotrophic Lateral Sclerosis279

Oct 2026~ConfirmedSTALE

CT.gov

00%

Competitive Landscape

4 competitors in Amyotrophic Lateral Sclerosis

IONSION363

Phase 3

TEVJF40 mg glatiramer acetate

Phase 2

NRSNPlacebo

Phase 2

TEVA40 mg glatiramer acetate

Phase 2

View Full Landscape

Drug Information

Target Indication

Amyotrophic Lateral Sclerosis

Clinical Trial

NCT05407324

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

CORT

Corcept Therapeutics Incorporated

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

Nab-paclitaxel 100 mg/m^2Phase 3

Ovarian Neoplasm

MifepristonePhase 3

Depressive Disorder, Major

Relacorilant 150 mg once daily (QD)Phase 3

Ovarian Cancer

mifepristone 600 mgPhase 3

Major Depressive Disorder

RelacorilantPhase 3

Recurrent Ovarian Cancer

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts